RAD51 and breast cancer: Therefore, oncogenic fusion tyrosine kinases inhibitors or RAD51 phosphorylation inhibitors can inhibit DDR of breast cancer cells and can be used in combination with chemotherapy drugs to enhance the sensitivity of breast cancer cells.